Serious adverse eventsk
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi
BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).
1 finding from 1 review
Serious adverse eventsm
NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).
1 finding from 1 review
Allergic adverse events · adults receiving mechanical ventilation for at least 48 hours
Topical plus systemic prophylaxis showed no clear difference in allergic adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Neonatal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal adverse events · women who have given birth vaginally, requiring analgesia for after‐birth pains.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ Stroke · cognitively healthy people in late life
Other NSAIDs showed no clear difference in adverse events – stroke compared with placebo (moderate certainty).
1 finding from 1 review
Maternal adverse events · pregnant women and their infants..
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Allergic adverse events · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes allergic adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review
Specific adverse events · adults with episodic tension‐type headache
1 finding from 1 review
Specific adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes adverse events At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review